VCYT

Veracyte Inc

VCYT, USA

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

https://www.veracyte.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VCYT
stock
VCYT

Veracyte (NASDAQ:VCYT) Stock Rating Lowered by Wall Street Zen Defense World

Read more →
VCYT
stock
VCYT

First Trust Advisors LP Raises Holdings in Veracyte, Inc. $VCYT Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$47.1

Analyst Picks

Strong Buy

7

Buy

2

Hold

1

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

122.44

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

2.71

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

1.52 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.40 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

31.82 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 120.17% of the total shares of Veracyte Inc

1.

FMR Inc

(10.3059%)

since

2025/06/30

2.

Vanguard Group Inc

(10.2964%)

since

2025/06/30

3.

BlackRock Inc

(9.8238%)

since

2025/06/30

4.

Artisan Partners Limited Partnership

(8.0357%)

since

2025/06/30

5.

iShares Core S&P Small-Cap ETF

(5.9248%)

since

2025/08/31

6.

ARK Investment Management LLC

(4.8303%)

since

2025/06/30

7.

Wellington Management Company LLP

(4.4155%)

since

2025/06/30

8.

State Street Corp

(4.029%)

since

2025/06/30

9.

Dimensional Fund Advisors, Inc.

(3.8419%)

since

2025/06/30

10.

ARK Innovation ETF

(3.7669%)

since

2025/08/28

12.

Vanguard Total Stock Mkt Idx Inv

(3.1043%)

since

2025/07/31

13.

ARK Disruptive Innovation Full Composite

(2.9991%)

since

2025/06/30

14.

Vanguard Explorer Inv

(2.8957%)

since

2025/06/30

15.

Fidelity Select Medical Tech and Devcs

(2.5422%)

since

2025/07/31

16.

Geode Capital Management, LLC

(2.455%)

since

2025/06/30

17.

Vanguard Small Cap Index

(2.4141%)

since

2025/07/31

18.

iShares Russell 2000 ETF

(2.4069%)

since

2025/08/31

19.

Amova Asset Management Americas, Inc

(2.0937%)

since

2025/06/30

20.

Sumitomo Mitsui Trust Group Inc

(2.0937%)

since

2025/06/30

21.

Goldman Sachs Group Inc

(1.9683%)

since

2025/06/30

22.

Bank of America Corp

(1.9317%)

since

2025/06/30

23.

GW&K Investment Management, LLC

(1.7855%)

since

2025/06/30

24.

Fidelity Select Health Care

(1.7795%)

since

2025/07/31

25.

SPDR® S&P Biotech ETF

(1.6888%)

since

2025/08/31

26.

First Trust NYSE Arca Biotech ETF

(1.5985%)

since

2025/08/28

27.

Artisan U.S. Mid-Cap Growth

(1.5015%)

since

2025/06/30

28.

Artisan Mid Cap Investor

(1.5015%)

since

2025/06/30

29.

ARK Genomic Revolution

(1.4796%)

since

2025/06/30

30.

ARK Genomic Revolution ETF

(1.4779%)

since

2025/08/28

31.

Vanguard Small Cap Growth Index Inv

(1.3641%)

since

2025/07/31

32.

First Trust Advisors L.P.

(1.3625%)

since

2025/06/30

33.

Amova ARK Disruptive Innovation A USD

(1.3117%)

since

2025/07/31

34.

Qube Research & Technologies

(1.2505%)

since

2025/06/30

35.

Northern Trust Corp

(1.2336%)

since

2025/06/30

36.

Squarepoint Ops LLC

(1.1407%)

since

2025/06/30

37.

BAMCO Inc

(1.115%)

since

2025/06/30

38.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0678%)

since

2025/07/31

39.

Strategic Advisers Fidelity US TtlStk

(1.0407%)

since

2025/07/31

40.

Fidelity Advisor Health Care I

(1.0169%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.51

EPS Estimate

0.3196

EPS Difference

0.1904

Surprise Percent

59.5745%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.3)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(6)
Net Net
Possible Net-Net(4)
Quality
High Quality(7.5)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.